AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
A benign reading from the Consumer Price Index report assuaged market fears about the path of borrowing costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback